Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche and Kosan conclude epothilone development

Roche and Kosan conclude epothilone development

26th October 2007

Roche and Kosan Biosciences have announced that they are to conclude their epothilone development and commercialisation collaboration with Kosan reacquiring worldwide rights to the programme.

Both pharmaceutical companies entered into the alliance in 2002 but changes to Roche’s research and development strategy will see the contract terminated after an appropriate transition period.

Kosan is set to have full control of the clinical development of its anti-tumour agent KOS-1584 and its other epothilone product candidates in the future.

Robert G Johnson, Kosan’s president and chief executive officer, detailed what full control would mean for the development of KOS-1584.

“Our control of the program permits us to determine the optimal strategy for advancing KOS-1584 into larger-scale clinical trials, potentially with a new collaborative partner which we plan to actively seek.”

He added that in the meantime Kosan would look to commence a Phase II clinical programme for the anti-tumour agent.

Dan Zabrowski, global head of Roche Pharma partnering, insisted that Roche believed that KOS-1584 was worthy to proceed to Phase II trials and that the collaboration had been a productive one.

Earlier this week, another of Roche’s collaborations, this time with Genmab, saw the first Phase I results released for a study investigating R1057 in patients with solid tumours.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.